This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04711252
Recruitment Status : Active, not recruiting
First Posted : January 15, 2021
Last Update Posted : March 26, 2024
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Tracking Information
First Submitted Date  ICMJE December 23, 2020
First Posted Date  ICMJE January 15, 2021
Last Update Posted Date March 26, 2024
Actual Study Start Date  ICMJE January 28, 2021
Estimated Primary Completion Date August 24, 2026   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 12, 2021)
Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1 [ Time Frame: From randomization until progression per RECIST 1.1 as assessed by the investigator at local site or death due to any cause (up to 5 years) ]
PFS is defined as the time from randomization to objective disease progression (as assessed by RECIST) or death.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 21, 2021)
  • Overall survival (OS) [ Time Frame: From randomization until the date of death due to any cause (up to 8 years) ]
    The OS is defined as the time from randomization to death due to any cause.
  • Second progression-free survival (PFS2) [ Time Frame: From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (up to 5 years) ]
    Time to second progression or death (PFS2) will be defined as the time from randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death.
  • Objective response rate (ORR) assessed by the Investigator as defined by RECIST version 1.1 [ Time Frame: From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (up to 5 years) ]
    ORR is defined as the proportion of patients who have a CR or partial response, as determined by the investigator at local site per RECIST 1.1.
  • Duration of response (DoR) assessed by the Investigator as defined by RECIST version 1.1 [ Time Frame: From the date of first documented response until date of documented progression per RECIST 1.1 as assessed by the investigator at local site or death due to any cause (up to 5 years) ]
    The DoR will be defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression.
  • Time to chemotherapy (TTC) [ Time Frame: From randomization until the earlier of the start date of chemotherapy or death due to any cause (up to 5 years) ]
    Time to chemotherapy is defined as the time from randomization until the earlier of the start date of chemotherapy or death due to any cause.
  • Time to first subsequent anti-cancer therapy (TFST) [ Time Frame: From randomization until the earlier of start date of the first subsequent anti-cancer therapy after discontinuation of randomized treatment, or death due to any cause (up to 5 years) ]
    TFST is defined as time from randomization until the earlier of start date of the first subsequent anti-cancer therapy after discontinuation of randomized treatment, or death due to any cause.
  • Clinical benefit rate at 24 weeks (CBR24) [ Time Frame: At least 23 weeks after randomisation ]
    CBR at 24 weeks is defined as the percentage of participants who have a complete response (CR) or partial response or who have stable disease (SD) per RECIST 1.1 as assessed by the investigator at local site for at least 23 weeks after randomization (to allow for an early assessment within the assessment window).
  • Time to second subsequent therapy (TSST) [ Time Frame: From randomization until the earlier of start date of the second subsequent anti-cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (up to 5 years) ]
    TSST is defined as time from randomization until the earlier of start date of the second subsequent anti-cancer therapy after discontinuation of first subsequent treatment, or death due to any cause.
  • Plasma concentration of AZD9833 at specified timepoints [ Time Frame: on Day 15 ]
    To assess the steady state PK of AZD9833 in combination with palbociclib in all participants who receive at least one dose of AZD9833 per the protocol, for whom there are at least one reportable PK concentration.
  • Change from baseline in EORTC QLQ-C30 scale scores [ Time Frame: From baseline to 24 weeks post progression (up to approximately 5 years) ]
    Change from baseline in EORTC QLQ-C30 scale scores for each patient at each post-baseline visit. The comparison will include all randomised patients, as randomised, with baseline and at least one post-baseline visit score for the scale score.
  • Change from baseline in EORTC QLQ-BR45 scale scores [ Time Frame: From baseline to 24 weeks post progression (up to approximately 5 years) ]
    Change from baseline in EORTC QLQ-BR45 scale scores for each patient at each post-baseline visit. The comparison will include all randomised patients, as randomised, with baseline and at least one post-baseline visit score for the scale score.
Original Secondary Outcome Measures  ICMJE
 (submitted: January 12, 2021)
  • Overall survival (OS) [ Time Frame: From randomization until the date of death due to any cause (up to 8 years) ]
    The OS is defined as the time from randomization to death due to any cause.
  • Progression-free survival 2 (PFS2) [ Time Frame: From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (up to 5 years) ]
    PFS2 is defined as the time from randomization to objective tumour progression on next-line treatment or death from any cause.
  • Objective response rate (ORR) assessed by the Investigator as defined by RECIST version 1.1 [ Time Frame: From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (up to 5 years) ]
  • Duration of response (DoR) assessed by the Investigator as defined by RECIST version 1.1 [ Time Frame: From the date of first documented response until date of documented progression per RECIST 1.1 as assessed by the investigator at local site or death due to any cause (up to 5 years) ]
    The DoR will be defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression.
  • Time to chemotherapy (TTC) [ Time Frame: From randomization until the earlier of the start date of chemotherapy or death due to any cause (up to 5 years) ]
    Time to chemotherapy is defined as the time from randomization until the earlier of the start date of chemotherapy or death due to any cause.
  • Time to first subsequent anti-cancer therapy (TFST) [ Time Frame: From randomization until the earlier of start date of the first subsequent anti-cancer therapy after discontinuation of randomized treatment, or death due to any cause (up to 5 years) ]
    TFST is defined as time from randomization until the earlier of start date of the first subsequent anti-cancer therapy after discontinuation of randomized treatment, or death due to any cause.
  • Clinical benefit rate at 24 weeks (CBR24) [ Time Frame: At least 23 weeks after randomisation ]
    CBR at 24 weeks is defined as the percentage of participants who have a complete response (CR) or partial response or who have stable disease (SD) per RECIST 1.1 as assessed by the investigator at local site for at least 23 weeks after randomization (to allow for an early assessment within the assessment window).
  • Time to second subsequent therapy (TSST) [ Time Frame: From randomization until the earlier of start date of the second subsequent anti-cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (up to 5 years) ]
    TSST is defined as time from randomization until the earlier of start date of the second subsequent anti-cancer therapy after discontinuation of first subsequent treatment, or death due to any cause.
  • Plasma concentration of AZD9833 at specified timepoints [ Time Frame: on Day 15 ]
    To assess the steady state PK of AZD9833 in combination with palbociclib in all participants who receive at least one dose of AZD9833 per the protocol, for whom there are at least one reportable PK concentration.
  • Change from baseline in EORTC QLQ-C30 scale scores [ Time Frame: From baseline to 24 weeks post progression (up to approximately 5 years) ]
    Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Scale scores range from 0-100. For functioning and global health status/ QoL scales, higher scores indicate better functioning or global health status/QoL. For symptom scales, higher scores indicate greater symptom burden.
  • Change from baseline in EORTC QLQ-BR45 scale scores [ Time Frame: From baseline to 24 weeks post progression (up to approximately 5 years) ]
    Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module (EORTC QLQ-BR45). Scale scores range from 0-100. For functioning scales, higher scores indicate better functioning. For symptom scales, higher scores indicate greater symptom burden.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Official Title  ICMJE SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Brief Summary

The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone receptor-positive (ER-positive), human epidermal growth factor 2-negative (HER2-negative) advanced/metastatic breast cancer.

INFORMATION FOR TRIAL PARTICIPANTS

In this trial, the researchers will look at how well camizestrant with palbociclib works, compared with anastrozole with palbociclib, in participants with breast cancer that has either spread into other parts of the body at the time of diagnosis, or has come back after at least 2 years of standard endocrine treatment.

Participants in this trial will have breast cancer that has ER proteins but does not have overexpression of HER2 protein.

Detailed Description

A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 (next generation oral SERD) in combination with palbociclib versus anastrozole in combination with palbociclib for the treatment of patients with ER-positive breast cancer. The goal of the study is to demonstrate superiority of AZD9833 over anastrozole in the context of combination with palbociclib in first line setting.

INFORMATION FOR TRIAL PARTICIPANTS

Researchers are looking for a better way to treat breast cancer.

In people with cancer, some cells have grown out of control to form tumours.

The trial drugs palbociclib, camizestrant, and anastrozole are designed to work by blocking the cancer's ability to grow. Camizestrant is also called AZD9833. Palbociclib and anastrozole are already available as treatments for people with certain type of breast cancer.

In this trial, the researchers want to find out how well taking camizestrant with palbociclib, or anastrozole with palbociclib, works in participants with breast cancer that has ER proteins but does not have overexpression of HER2 protein.

The researchers will look at which trial treatments help the participants live longer with cancer before it gets worse.

The trial will split participants into 2 groups:

  • Participants in Group 1 will take camizestrant, palbociclib, and a placebo matched with anastrazole.
  • Participants in Group 2 will take anastrozole, palbociclib, , and a placebo matched with camizestrant.

A placebo looks like a treatment but does not have any medicine in it.

A computer program will be used to randomly choose the treatments each participant gets. This helps make sure the groups are chosen fairly. Researchers do this so that comparing the results of each treatment will be as accurate as possible.

The participants will take their trial treatments in periods called "cycles". Each cycle will last 28 days. During each cycle, the participants will take:

  • camizestrant or anastrozole once daily by mouth
  • palbociclib once daily by mouth for 21 days. Then, they will not take any palbociclib for 7 days

Some participants will also get either goserelin or leuprorelin once every month. Participants could get goserelin or leuprorelin if:

  • They are medically determined yet to reach menopause status
  • They are male

They will get this treatment as an injection under the skin or into a muscle. Goserelin and leuprorelin work by decreasing the amount of sex hormones made by the body which will lead to reduction of ER production. This can help stop breast cancer from growing.

Participants will take trial treatment until the cancer gets worse or they leave the trial.

Participants will visit their trial site several times throughout the trial. At these visits, the trial doctors will check the health of the participants. They will also take blood samples and do scans of the participants' tumors.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE ER-Positive HER2-Negative Breast Cancer
Intervention  ICMJE
  • Drug: AZD9833
    Dosage formulation: AZD9833 tablets will be administered orally
  • Drug: Anastrozole
    Dosage formulation: Anastrozole tablets will be administered orally.
  • Drug: Anastrozole placebo
    Dosage formulation: anastrozole placebo tablets will be administrated orally.
  • Drug: AZD9833 placebo
    Dosage formulation: AZD9833 placebo tablets will be administrated orally.
  • Drug: Palbociclib
    Dosage formulation: palbociclib tablets/capsules will be administered orally
  • Drug: Luteinizing hormone-releasing hormone (LHRH) agonist
    Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
Study Arms  ICMJE
  • Experimental: AZD9833 + palbociclib
    The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125 mg for 21 consecutive days followed by 7 days off treatment) + anastrozole placebo (1 mg, PO, once daily)
    Interventions:
    • Drug: AZD9833
    • Drug: Anastrozole placebo
    • Drug: Palbociclib
    • Drug: Luteinizing hormone-releasing hormone (LHRH) agonist
  • Active Comparator: Anastrozole + palbociclib
    The patients will recieve Anastrozole (1 mg, PO, once daily) + palbociclib (PO, once daily, 125 mg for 21 consecutive days followed by 7 days off treatment) + AZD9833 placebo (PO, once daily)
    Interventions:
    • Drug: Anastrozole
    • Drug: AZD9833 placebo
    • Drug: Palbociclib
    • Drug: Luteinizing hormone-releasing hormone (LHRH) agonist
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: February 9, 2024)
1370
Original Estimated Enrollment  ICMJE
 (submitted: January 12, 2021)
1342
Estimated Study Completion Date  ICMJE February 1, 2029
Estimated Primary Completion Date August 24, 2026   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

INCLUSION CRITERIA

Full list of inclusion criteria

  • Pre-/peri-menopausal women or men can be enrolled if amenable to be treated with concomitant, approved LHRH agonists for the duration of the study treatment.
  • De novo Stage 4 disease, or recurrence from early stage disease after at least 24 months of standard adjuvant endocrine therapy. Note that at least 12 months must have elapsed since the patient's last dose of adjuvant AI therapy without disease progression on treatment. Note that a 2-week washout period is required after the last dose of tamoxifen prior to randomisation.
  • Histologically or cytologically documented diagnosis of ER+, HER2-negative breast cancer based on local laboratory results.
  • Previously untreated with any systemic anti-cancer therapy for their locoregionally recurrent or metastatic ER+ disease.
  • Measurable disease as defined per RECIST v.1.1 OR at least one lytic or mixed (lytic + sclerotic) bone lesion with a soft tissue component that can be assessed by CT or MRI.
  • Eastern Cooperative Oncology Group performance status of 0 or 1.
  • Adequate organ and marrow function.
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

INFORMATION FOR TRIAL PARTICIPANTS

Participants can join the trial if they:

  • Have breast cancer that cannot be treated with surgery or radiation
  • Have breast cancer that has already spread into other parts of the body at the time of diagnosis, or has come back after at least 2 years of a standard endocrine treatment
  • Have ER proteins but not overexpression of HER2 protein in their tumors
  • Have never received any type of cancer therapy that affects the whole body for advanced breast cancer
  • Are able to do their daily activities

EXCLUSION CRITERIA

Full list of exclusion criteria

  • Previous neoadjuvant or adjuvant treatment with an AI treatment +/- CDK4/6 inhibitor with disease recurrence while on or within 12 months of completing treatment.
  • Prior exposure to AZD9833, other investigational SERDs/endocrine agents or fulvestrant.
  • Participation in another clinical study with a study treatment or investigational medicinal device administered in the last 4 weeks prior to randomization or concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
  • Advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term and/or impending visceral crisis
  • Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease.
  • Any clinically important and symptomatic heart disease .
  • Currently pregnant (confirmed with positive pregnancy test) or breast-feeding.
  • As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, renal transplant and active bleeding diseases) which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.
  • Any concurrent anti-cancer treatment.
  • Active infection including tuberculosis, HBV and HCV.

INFORMATION FOR TRIAL PARTICIPANTS

Participants cannot join the trial if they:

  • Have uncontrolled cancer that has spread to the brain or the spinal cord
  • Have received certain treatments for cancer in the past but the cancer came back within 1 year
  • Had certain types of tumors in the past, which the study doctors think could come back
  • Are currently taking any treatment for cancer or are taking medications or supplements that affect certain proteins in the body
  • Have any major health problem, infection, or surgery that could make it difficult or dangerous to participate in this trial, such as tuberculosis, HIV, heart problems, or a kidney transplant

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 130 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Austria,   Belgium,   Bulgaria,   Canada,   Chile,   China,   Czechia,   France,   Germany,   Hungary,   India,   Italy,   Japan,   Korea, Republic of,   Malaysia,   Mexico,   Norway,   Poland,   Portugal,   Russian Federation,   Slovakia,   Spain,   Switzerland,   Taiwan,   Turkey,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04711252
Other Study ID Numbers  ICMJE D8532C00001
2020-002276-12 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting Materials: Study Protocol
Supporting Materials: Statistical Analysis Plan (SAP)
Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access Criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
URL: https://astrazenecagroup-dt.pharmacm.com/DT/Home
Current Responsible Party AstraZeneca
Original Responsible Party Same as current
Current Study Sponsor  ICMJE AstraZeneca
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account AstraZeneca
Verification Date March 2024

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP